ClinicalTrials.gg
CompletedNCT02760433CREDO 3Updated Sep 21, 2023Results posted

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

A Phase 3 interventional study of Olokizumab and Placebo in Rheumatoid Arthritis, sponsored by R-Pharm International, LLC. Completed at 116 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by R-Pharm International, LLC (part of R-Pharm) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
368
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing olokizumab in Arthritis, Rheumatoid — none open to participants now, none under way, none of them phase 3. olokizumab · Arthritis, Rheumatoid.

Enrollment
4th of 10
368 · median 206
Started
2017
with 1 other
Phase 3
4 of 10
none open now
Registered
6th of 10
by date
Lead sponsor
5 of 10
R-Pharm International, LLC

Among the 10 studies testing olokizumab in Arthritis, Rheumatoid, this one is the 4th largest by enrollment, is one of 2 that started in 2017, is one of 4 in phase 3, and was the 6th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

None of the 10 studies testing olokizumab in Arthritis, Rheumatoid is open now. The open studies under Arthritis, Rheumatoid, anywhere →

About olokizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing olokizumab in Arthritis, Rheumatoid as a file.
02

Study summary

The purpose of this study was to determine how effective and safe the study drug Olokizumab was in patients with Rheumatoid Arthritis (RA) who had been already receiving, but not fully responding to treatment with an existing medication called a tumour necrosis factor alpha inhibitor

The primary objective of this study was to evaluate the efficacy of olokizumab (OKZ) 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) relative to placebo in subjects with moderately to severely active rheumatoid arthritis (RA) inadequately controlled by TNF-α inhibitor (TNFi) therapy.

Read the detailed description

The goal of this Phase III study was to assess the efficacy, safety and tolerability of OKZ in subjects with moderately to severely active RA who had responded inadequately to TNFi therapy. The primary endpoint of the trial was assessed at Week 12. Olokizumab was expected to reduce the disease activity and improve physical function. The study was expected to provide safety information in a large group of subjects over at least a 24 week period.

This was a randomized, double-blind, parallel-group, placebo-controlled, multicenter study. This study included a 4-week Screening Period, a double-blind Treatment Period from Week 0 to Week 24, and a Safety FollowUp Period from Week 24 to Week 44.

A total of 350 subjects were planned to be randomized.Subjects were assessed for eligibility to enter the study during a 4-week Screening Period. Eligible subjects were randomized at Visit 2 in a 2:2:1 ratio in one of 3 treatment groups (planned 140, 140, and 70 subjects per group, respectively) :

  1. Olokizumab 64 mg q4w: SC injection of OKZ 64 mg q4w (alternating with SC injection of placebo OKZ q4w to maintain blinding) + MTX for 24 weeks,
  2. Olokizumab 64 mg q2w: SC injection of OKZ 64 mg q2w + MTX for 24 weeks or
  3. Placebo: SC injection of placebo q2w + MTX for 16 weeks.

Subjects who received placebo were re-randomized at Week 16 to receive 64 mg OKZ q4w + Methotrexate or 64 mg OKZ q2w +Methotrexate for 8 weeks.

Throughout the double-blind Treatment Period, all subjects were required to remain on a stable dose of background MTX with a stable route of administration. Concomitant treatment with folic acid was required for all subjects. The last dose of OKZ was administered at Week 20 for subjects receiving OKZ 64 mg q4w and at Week 22 for subjects receiving OKZ 64 mg q2w.

Following Visit 2 (randomization; Week 0), subjects returned to the study site at least every 2 weeks through Week 24 for response and safety assessments.

At Week 14, subjects who did not improve by at least 20% in both swollen and tender joint counts were classified as nonresponders and were administered sulfasalazine and/or hydroxychloroquine as rescue medication in addition to the assigned treatment.

After completion of the 24-week double-blind Treatment Period, subjects either rolled over into the long-term open-label extension (OLE) study or entered the Safety Follow-Up Period. During the Safety Follow-Up Period, subjects returned for visits +4, +8, and +22 weeks after the last dose of study treatment.

Subjects who discontinued randomized treatment prematurely were required to come for the End of Treatment (EoT) Visit 2 weeks after the last study treatment administration and then continue with the scheduled study visits.

Adverse events (AEs) were assessed throughout the study (starting when the subject signed the informed consent form) and evaluated using the Common Terminology Criteria for Adverse Events Version 4.0. There was ongoing monitoring of safety events, including laboratory findings, by the Sponsor or the Sponsor's designee. In addition, safety was assessed throughout the study by an independent Data Safety Monitoring Board and potential major adverse cardiac events were evaluated by an independent Cardiovascular Adjudication Committee.

The study was conducted at 123 sites across 11 countries globally (in US,EU, Russian Federation, Asia, Latin America)

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • moderate Rheumatoid Arthritis
  • severe Rheumatoid Arthritis
  • Olokizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects may be enrolled in the study only if they meet all of the following criteria.

  • Subjects willing and able to sign
  • Subjects must have a diagnosis of adult onset RA classified by ACR/EULAR 2010 revised classification criteria for RA for at least 24 weeks prior to Screening.

(If the subject was diagnosed according to ACR 1987 criteria previously, the Investigator may classify the subject per ACR 2010 retrospectively, using available source data.)

  • Treatment with oral, SC, or intramuscular (IM) MTX for at least 12 weeks prior to Screening at a dose of 15 to 25 mg/week (or ≥10 mg/week if there is documented intolerance to higher doses)

    • The dose and means of administering MTX must have been stable for at least 6 weeks prior to Screening.
  • Subjects must be willing to take folic acid or equivalent throughout the study.
  • Subjects must have moderately to severely active RA disease as defined by all of the following:

    • ≥6 tender joints (68 joint count) at Screening and baseline; and
    • ≥6 swollen joints (66 joint count) at Screening and baseline; and
    • C-reactive protein (CRP) above (ULN) at Screening based on the central laboratory results.
  • Subjects must have a documented inadequate response to treatment (i.e., TNFi failure) with ≥1 licensed TNFi following at least 12 weeks of therapy with that agent. Inadequate response to treatment is classified as either:

    • Primary failure: The absence of any documented response; or
    • Secondary failure: Documented initial response with subsequent loss of that response or partial response

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of any other inflammatory arthritis or systemic rheumatic disease (e.g., gout, psoriatic or reactive arthritis, Crohn's disease, Lyme disease, juvenile idiopathic arthritis, or systemic lupus erythematosus) (However, subjects may have secondary Sjogren's syndrome or hypothyroidism.)
  • Subjects who are Steinbrocker class IV functional capacity (incapacitated, largely or wholly bed-ridden or confined to a wheelchair, with little or no self-care)
  • Prior exposure to any licensed or compound directly or indirectly targeting Interleukin (IL) 6 or IL 6R (including tofacitinib or other Janus kinases and spleen tyrosine kinase [SYK] inhibitors)
  • Prior treatment with cell depleting therapies including anti CD20 or investigational agents (e.g., CAMPATH, anti CD4, anti CD5, anti CD3, and anti CD19) with the exception of rituximab, which is allowed if it was discontinued at least 24 weeks prior to baseline (rituximab should not be discontinued to facilitate a subject's participation in the study, but should instead have been previously discontinued as part of a subject's medical management of RA).
  • Prior use of bDMARDs, within the following windows prior to baseline (bDMARDs should not be discontinued to facilitate a subject's participation in the study, but should instead have been previously discontinued as part of a subject's medical management of RA):

    1. 4 weeks for etanercept and anakinra
    2. 8 weeks for infliximab
    3. 10 weeks for adalimumab, certolizumab, and golimumab
    4. 12 weeks for abatacept
  • Use of parenteral and/or intra-articular within 4 weeks prior to baseline
  • Use of oral glucocorticoids greater than 10 mg/day prednisone (or equivalent) or change in dosage within 2 weeks prior to baseline
  • Prior documented history of no response to hydroxychloroquine and sulfasalazine
  • Prior use of cDMARDs (other than MTX) within the following windows prior to baseline (cDMARDs should not be discontinued to facilitate a subject's participation in the study, but should instead have been previously discontinued as part of a subject's medical management of RA):

    1. 4 weeks for sulfasalazine, azathioprine, cyclosporine, hydroxychloroquine, chloroquine, gold, penicillamine, minocycline, or doxycycline
    2. 12 weeks for leflunomide unless the subject has completed the following elimination procedure at least 4 weeks prior to baseline: Cholestyramine at a dosage of 8 grams 3 times daily for at least 24 hours, or activated charcoal at a dosage of 50 grams 4 times daily for at least 24 hours
    3. 24 weeks for cyclophosphamide
  • Vaccination with in the 6 weeks prior to baseline or planned vaccination with live vaccines during the study
  • Participation in any other investigational drug study within 30 days or 5 times the terminal half-life of the investigational drug, whichever is longer, prior to baseline
  • Other treatments for RA (e.g., Prosorba Device/Column) within 6 months prior to baseline
  • Use of intra-articular hyaluronic acid injections within 4 weeks prior to baseline
  • Use of non steroidal anti inflammatory drugs (NSAIDs) on unstable dose or switching of NSAIDs within 2 weeks prior to baseline
  • Previous participation in this study (randomized) or another study of OKZ
  • Subjects with concurrent acute or chronic viral or C infection as detected by blood tests at Screening (e.g., positive for hepatitis B surface antigen [HBsAg], total hepatitis B core antibody [anti-HBc], or virus antibody [HCV Ab])

    a) subjects who are positive for hepatitis B surface antibodies (anti-HBs), but negative for HBsAg and anti-HBc, will be eligible.

  • Subjects with infection
  • Subjects with:

    1. Suspected or confirmed current active tuberculosis (TB) disease or a history of active TB disease.
    2. Close contact (i.e., sharing the same household or other enclosed environment, such as a social gathering place, workplace, or facility, for extended periods during the day) with an individual with active TB within 1.5 years prior to Screening
  • Concurrent or a history of malignancy within the last 5 years (with the exception of successfully treated carcinoma of the cervix in situ and successfully treated basal cell carcinoma and squamous cell carcinoma not less than 1 year prior to Screening [and no more than 3 excised skin cancers within the last 5 years prior to Screening])
  • Subjects with any infection requiring oral antibiotic or antiviral therapy in the 2 weeks prior to Screening or at baseline, injectable anti-infective therapy in the last 4 weeks prior to baseline, or serious or recurrent infection with history of hospitalization in the 6 months prior to baseline
  • Subjects with evidence of disseminated herpes zoster infection, zoster encephalitis, meningitis, or other non-self-limited herpes zoster infections in the 6 months prior to baseline
  • Subjects with planned surgery during the study or surgery ≤ 4 weeks prior to Screening and from which the subject has not fully recovered, as judged by the Investigator
  • Subjects with diverticulitis or other symptomatic GI conditions that might predispose the subject to perforations, including subjects with history of such predisposing conditions (e.g., diverticulitis, GI perforation, or ulcerative colitis)
  • Pre-existing central nervous system demyelinating disorders (e.g., multiple sclerosis and optic neuritis)
  • History of chronic alcohol or drug abuse as judged by the Investigator
  • Subjects with a known to any component of the OKZ drug product or placebo
  • Subjects with a known hypersensitivity or to any component of the rescue medication
  • History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies
  • Female subjects who are pregnant, currently lactating, have lactated within the last 12 weeks, or who are planning to become pregnant during the study or within 6 months of the last dose of study treatment
  • Female subjects of (unless permanent cessation of menstrual periods, determined retrospectively after a woman has experienced 12 months of natural amenorrhea as defined by the amenorrhea with underlying status [e.g., correlative age] or 6 months of natural amenorrhea with documented serum follicle-stimulating hormone levels >40 mIU/mL and estradiol \<20 pg/mL) who are not willing to use a highly effective method of during the study and for at least 6 months after the last administration of study treatment

OR

Male subjects with partners of childbearing potential not willing to use a highly effective method of contraception during the study and for at least 3 months after the last administration of study treatment.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
368 participants (actual)

Study arms

  • Experimental
    Arm 1: Olokizumab q4w

    Olokizumab 64mg subcutaneous q4w + placebo + Methotrexate Olokizumab 64 mg subcutaneous q4w + placebo+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)

    Drug: Olokizumab · Drug: Placebo

  • Experimental
    Arm 2: Olokizumab q2w

    Olokizumab 64mg subcutaneous q2w + Methotrexate 64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)

    Drug: Olokizumab

  • Placebo comparator
    Arm 3: Placebo q2w

    Placebo q2w subcutaneous + Methotrexate Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) Starting at Week 16, all subjects in the placebo group were randomized in a blinded fashion to receive either OKZ 64 mg q2w or OKZ 64 mg q4w; equal numbers of subjects were planned to be assigned to each OKZ treatment group.

    Drug: Placebo

Interventions

  • 160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial

  • DrugPlacebo

    sodium chloride 0.9% solution provided as either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response

    The difference between OKZ and placebo in the percentage of subjects achieving an ACR20 response and remaining on randomized treatment and in the study at Week 12. A responder is defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12. American College of Rheumatology 20 % response is a composite defined as a ≥ 20% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥20% improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)

    Time frame: at Week 12

Secondary outcomes

  1. Percentage of Subjects Achieving Low Disease Activity

    Defined as Disease Activity Score 28-joint count (DAS28) C-reactive protein (CRP) \<3.2, and remaining on randomized treatment and in the study at Week 12

    Time frame: at Week 12

  2. Improvement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire Disability Index (HAQ-DI)

    Change of physical ability from baseline (the last available assessment prior to the first dose of the study treatment) to week 12, as measured by HAQ-DI. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions.The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3 where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question. A decrease from baseline indicates improvement for HAQ-DI.The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered. The HAQ-DI total score ranges from 0 (the best outcome) to 3 (the worst outcome).

    Time frame: Baseline to Week 12

  3. Percentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response

    Difference between OKZ and placebo in the percentage of subjects achieving an ACR50 response and remaining on randomized treatment and in the study at Week 12. American College of Rheumatology 50% Response is a composite defined as ≥50%, improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥50%, improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)

    Time frame: at Week 12

  4. Percentage of Subjects With Clinical Disease Activity Index (CDAI) ≤ 2.8 (Remission)

    Difference between OKZ and placebo in the percentage of subjects with Clinical Disease Activity Index (CDAI) ≤2.8 (remission) and remaining on randomized treatment and in the study at Week 12

    Time frame: at Week 12

07

Results

Posted Jul 21, 2021

Participant flow

Enrollment was conducted at 123 clinical sites across 11 countries (US,EU, Russian Federation, Asia, Latin America). 718 subjects were screened and 368 subjects were enrolled (randomized) and treated, 318 subjects completed the study. A total of 368 subjects were analyzed for efficacy in the ITT Population and 368 subjects were analyzed for safety in the Safety Population.

Participant flow — Overall Study
MilestoneArm 1: Olokizumab q4wArm 2: Olokizumab q2wArm 4: Placebo-OKZ 64 mg q4wArm 5: Placebo-OKZ 64 mg q2wArm 8: Placebo Only
Started161138263211
Completed13412825301
Not completed27101210
Withdrew: Lost to follow-up10100
Withdrew: Withdrawal by subject239029
Withdrew: Lack of response at week 1400001
Withdrew: Subject refused to continue the study10000
Withdrew: Subject was taking prohibited medications and refused to stop.20000
Withdrew: Ongoing adverse events (low platelet count) with long interruptions of investigational product01000

Outcome measures

PrimaryPercentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response

The difference between OKZ and placebo in the percentage of subjects achieving an ACR20 response and remaining on randomized treatment and in the study at Week 12. A responder is defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12. American College of Rheumatology 20 % response is a composite defined as a ≥ 20% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥20% improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)

Time frame:
at Week 12
Reported as:
Count of participants · Participants
Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response
ParticipantsArm 1: Olokizumab 64 mg q4wArm 2: Olokizumab 64 mg q2wArm 3: Placebo q2w
Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response968428
Statistical analysis
  • Arm 1: Olokizumab 64 mg q4w vs Arm 3: Placebo q2w · Chi-squared · p = 0.004 · Risk difference (rd): 0.190 · 97.5% CI 0.030 to 0.3372x2 chi-square test
  • Arm 2: Olokizumab 64 mg q2w vs Arm 3: Placebo q2w · Chi-squared · p = 0.0029 · Risk difference (rd): 0.203 · 97.5% CI 0.038 to 0.3532x2 chi-square test
SecondaryPercentage of Subjects Achieving Low Disease Activity

Defined as Disease Activity Score 28-joint count (DAS28) C-reactive protein (CRP) \<3.2, and remaining on randomized treatment and in the study at Week 12

Time frame:
at Week 12
Reported as:
Count of participants · Participants
Percentage of Subjects Achieving Low Disease Activity
ParticipantsArm 1: Olokizumab q4wArm 2: Olokizumab q2wArm 3: Placebo q2w
Percentage of Subjects Achieving Low Disease Activity47558
Statistical analysis
  • Arm 1: Olokizumab q4w vs Arm 3: Placebo q2w · Chi-squared · p = 0.0021 · Risk difference (rd): 0.176 · 97.5% CI 0.041 to 0.2812x2 chi-square test
  • Arm 2: Olokizumab q2w vs Arm 3: Placebo q2w · Chi-squared · p = <0.0001 · Risk difference (rd): 0.283 · 97.5% CI 0.139 to 0.3962x2 chi-square test
SecondaryImprovement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire Disability Index (HAQ-DI)

Change of physical ability from baseline (the last available assessment prior to the first dose of the study treatment) to week 12, as measured by HAQ-DI. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions.The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3 where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question. A decrease from baseline indicates improvement for HAQ-DI.The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered. The HAQ-DI total score ranges from 0 (the best outcome) to 3 (the worst outcome).

Time frame:
Baseline to Week 12
Reported as:
Mean · score on a scale
Improvement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire Disability Index (HAQ-DI)
score on a scaleArm 1: Olokizumab q4wArm 2: Olokizumab q2wArm 3: Placebo q2w
Improvement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire Disability Index (HAQ-DI)-0.39 ± 0.048-0.49 ± 0.056-0.32 ± 0.063
Statistical analysis
  • Arm 1: Olokizumab q4w vs Arm 3: Placebo q2w · ANCOVA · p = =0.1814 (p-value was greater than the threshold p-value of 0.0125) · Least squares mean difference: -0.07 · 97.5% CI -0.26 to 0.11
  • Arm 2: Olokizumab q2w vs Arm 3: Placebo q2w · ANCOVA · p = =0.0227 (p-value was greater than the threshold p-value of 0.0125) · Least squares mean difference: -0.17 · 97.5% CI -0.35 to 0.02
SecondaryPercentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response

Difference between OKZ and placebo in the percentage of subjects achieving an ACR50 response and remaining on randomized treatment and in the study at Week 12. American College of Rheumatology 50% Response is a composite defined as ≥50%, improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥50%, improvement from baseline in at least 3 of the 5 remaining core set measures: * Patient Global Assessment of Disease Activity (VAS) * Patient Assessment of Pain (VAS) * HAQ-DI * Physician Global Assessment (VAS) * Level of acute phase reactant (CRP)

Time frame:
at Week 12
Reported as:
Count of participants · Participants
Percentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response
ParticipantsArm 1: Olokizumab q4wArm 2: Olokizumab q2wArm 3: Placebo q2w
Percentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response524611
Statistical analysis
  • Arm 1: Olokizumab q4w vs Arm 3: Placebo q2w · Risk difference (rd): 0.164 · 97.5% CI 0.020 to 0.278
  • Arm 2: Olokizumab q2w vs Arm 3: Placebo q2w · Risk difference (rd): 0.174 · 97.5% CI 0.027 to 0.294
SecondaryPercentage of Subjects With Clinical Disease Activity Index (CDAI) ≤ 2.8 (Remission)

Difference between OKZ and placebo in the percentage of subjects with Clinical Disease Activity Index (CDAI) ≤2.8 (remission) and remaining on randomized treatment and in the study at Week 12

Time frame:
at Week 12
Reported as:
Count of participants · Participants
Percentage of Subjects With Clinical Disease Activity Index (CDAI) ≤ 2.8 (Remission)
ParticipantsArm 1: Olokizumab q4wArm 2: Olokizumab q2wArm 3: Placebo q2w
Percentage of Subjects With Clinical Disease Activity Index (CDAI) ≤ 2.8 (Remission)590
Statistical analysis
  • Arm 1: Olokizumab q4w vs Arm 3: Placebo q2w · Risk difference (rd): 0.031 · 97.5% CI -0.052 to 0.083means continuity correction applied because expected cell counts \< 5
  • Arm 2: Olokizumab q2w vs Arm 3: Placebo q2w · Risk difference (rd): 0.065 · 97.5% CI -0.023 to 0.134means continuity correction applied because expected cell counts \< 5

Adverse events

Collected over All AEs were collected from the signature of the informed consent form until the last visit of the subject in the study (up to 22 weeks after the final dose of study treatment) regardless of relationship to study treatment, up to approximately 44 weeks. Any SAE with a start date after the Safety Follow-Up Period was not required to be reported unless the Investigator thought that the event might be related to either the study treatment, study treatment administration, or a protocol procedure. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1: OKZ 64 mg q4w0/160 (0%)6/160 (3.8%)38/160 (23.8%)
Arm 2: OKZ 64 mg q2w0/139 (0%)12/139 (8.6%)38/139 (27.3%)
Arm 3: Placebo q2w0/69 (0%)0/69 (0%)16/69 (23.2%)
Arm 4: Placebo-OKZ 64 mg q4w0/26 (0%)0/26 (0%)2/26 (7.7%)
Arm 5: Placebo-OKZ 64 mg q2w0/32 (0%)0/32 (0%)8/32 (25%)
Arm 6: Any OKZ 64 mg q4w0/186 (0%)6/186 (3.2%)40/186 (21.5%)
Arm 7: Any OKZ 64 mg q2w0/171 (0%)12/171 (7%)46/171 (26.9%)
Total0/368 (0%)18/368 (4.9%)98/368 (26.6%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventArm 1: OKZ 64 mg q4wArm 2: OKZ 64 mg q2wArm 3: Placebo q2wArm 4: Placebo-OKZ 64 mg q4wArm 5: Placebo-OKZ 64 mg q2wArm 6: Any OKZ 64 mg q4wArm 7: Any OKZ 64 mg q2wTotal
CellulitisInfections and infestations1/1601/1390/690/260/321/1861/1712/368
Pilonidal cystInfections and infestations0/1601/1390/690/260/320/1861/1711/368
SepsisInfections and infestations0/1601/1390/690/260/320/1861/1711/368
Aspartate aminotransferase increasedInvestigations0/1601/1390/690/260/320/1861/1711/368
Transaminases increasedInvestigations0/1601/1390/690/260/320/1861/1711/368
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/1601/1390/690/260/320/1861/1711/368
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/1601/1390/690/260/320/1861/1711/368
OsteoarthritisMusculoskeletal and connective tissue disorders0/1601/1390/690/260/320/1861/1711/368
CholecystitisHepatobiliary disorders0/1601/1390/690/260/320/1861/1711/368
Hip fractureInjury, poisoning and procedural complications0/1601/1390/690/260/320/1861/1711/368
Most frequent other events
Most frequent other events
EventArm 1: OKZ 64 mg q4wArm 2: OKZ 64 mg q2wArm 3: Placebo q2wArm 4: Placebo-OKZ 64 mg q4wArm 5: Placebo-OKZ 64 mg q2wArm 6: Any OKZ 64 mg q4wArm 7: Any OKZ 64 mg q2wTotal
Alanine aminotransferase increasedInvestigations13/16010/1390/690/261/3213/18611/17124/368
NasopharyngitisInfections and infestations7/1609/1391/690/261/327/18610/17118/368
Aspartate aminotransferase increasedInvestigations8/1609/1391/690/261/328/18610/17119/368
Latent tuberculosisInfections and infestations6/1604/1390/691/262/327/1866/17113/368
DiarrhoeaGastrointestinal disorders3/1606/1390/690/262/323/1868/17111/368
AnaemiaBlood and lymphatic system disorders1/1601/1394/690/262/321/1863/1718/368
Upper respiratory tract infectionInfections and infestations6/1605/1394/690/261/326/1866/17116/368
InfluenzaInfections and infestations0/1605/1394/690/261/320/1866/17110/368
Injection site erythemaGeneral disorders7/1601/1390/690/260/327/1861/1718/368
HypertensionVascular disorders1/1604/1393/691/260/322/1864/1719/368

Baseline characteristics

Arm 3 (Placebo) combines all subjects from Arms 4, 5 and 8. Starting at Week 16, subjects in the placebo group were randomized in a blinded fashion to receive either OKZ 64 mg q2w or OKZ 64 mg q4w. (Efficacy data are presented for Arm 1, Arm 2, and Arm 3.)

Age, Categorical
Age, Categorical(Participants)Arm 1: Olokizumab q4wArm 2: Olokizumab q2wArm 4: Placebo-OKZ 64 mg q4wArm 5: Placebo-OKZ 64 mg q2wArm 8: Placebo OnlyTotal
<=18 years000000
Between 18 and 65 years13211420277300
>=65 years292465468
Age, Continuous
Age, Continuous(years)Arm 1: Olokizumab q4wArm 2: Olokizumab q2wArm 4: Placebo-OKZ 64 mg q4wArm 5: Placebo-OKZ 64 mg q2wArm 8: Placebo OnlyTotal
Mean53.9 ± 11.6853.4 ± 12.6853.5 ± 14.1353.9 ± 11.6748.9 ± 18.2853.5 ± 12.43
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1: Olokizumab q4wArm 2: Olokizumab q2wArm 4: Placebo-OKZ 64 mg q4wArm 5: Placebo-OKZ 64 mg q2wArm 8: Placebo OnlyTotal
Female13012220278307
Male311665361
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm 1: Olokizumab q4wArm 2: Olokizumab q2wArm 4: Placebo-OKZ 64 mg q4wArm 5: Placebo-OKZ 64 mg q2wArm 8: Placebo OnlyTotal
Asian3611011
Black of African American111101023
White139110192410302
Other/Mixed81166132
Region of Enrollment
Region of Enrollment(participants)Arm 1: Olokizumab q4wArm 2: Olokizumab q2wArm 4: Placebo-OKZ 64 mg q4wArm 5: Placebo-OKZ 64 mg q2wArm 8: Placebo OnlyTotal
Colombia3523013
Argentina141112028
South Korea120104
Hungary81023124
United States63441083128
Czechia171322236
Brazil81113124
Poland5502113
Mexico272888273
Germany310004
Russia12800121
Body Mass Index (BMI),Continuous
Body Mass Index (BMI),Continuous(kg/m^2)Arm 1: Olokizumab q4wArm 2: Olokizumab q2wArm 4: Placebo-OKZ 64 mg q4wArm 5: Placebo-OKZ 64 mg q2wArm 8: Placebo OnlyTotal
Mean29.218 (17.99 to 56.25)28.755 (17.78 to 57.93)28.895 (20.74 to 49.93)28.467 (17.82 to 37.60)26.976 (21.09 to 38.37)28.888 (17.78 to 57.93)
08

Study locations

116 sites
  • Arizona Arthritis & Rheumatology Associates, P.C.
    Phoenix, Arizona 85032, United States
  • CHI St. Vincent Hot Springs
    Hot Springs, Arkansas 71913, United States
  • Medvin Clinical Research
    Covina, California 91722, United States
  • TriWest Research Associates, LLC
    El Cajon, California 92020-4124, United States
  • Saint Jude Heritage Medical Grp
    Fullerton, California 92835, United States
  • С V Mehta MD Med Corp.
    Hemet, California 92543, United States
  • Advanced Medical Research, LLC
    Lakewood, California 90623, United States
  • Stanford University School of Medicine
    Palo Alto, California 94304, United States
  • Riverside Medical Clinic
    Riverside, California 92506, United States
  • East Bay Rheumatology Medical Group, Inc.
    San Leandro, California 94578, United States
  • Inland Rheumatology Clinical Trials, Inc.
    Upland, California 91786, United States
  • Denver Arthritis Clinic
    Denver, Colorado 80230, United States
  • Javed Rheumatology Associates
    Newark, Delaware 19713, United States
  • RASF - Clinical Research Center
    Boca Raton, Florida 33486, United States
  • Suncoast Research Group LLC
    Miami, Florida 33135, United States
  • Omega Research Consultants
    Orlando, Florida 32810, United States
  • Family Clinical Trials, LLC.
    Pembroke Pines, Florida 33026, United States
  • AdventHealth Medical Group, PA
    Tampa, Florida 33614, United States
  • Institute of Arthritis Research
    Idaho Falls, Idaho 83404, United States
  • University of Kansas Hospital
    Kansas City, Kansas 66160, United States
  • Graves Gilbert Clinic
    Bowling Green, Kentucky 42101, United States
  • The Arthritis & Diabetes Clinic, Inc.
    Monroe, Louisiana 71203, United States
  • Klein and Associates, M.D., P.A.
    Hagerstown, Maryland 21740, United States
  • The Center for Rheumatology and Bone Research
    Wheaton, Maryland 20902, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01605, United States
  • Glacier View Research Instutute-Rheumatology
    Kalispell, Montana 59901, United States
  • Arthritis & Osteoporosis Associates, PA
    Freehold, New Jersey 07728, United States
  • Lovelace Scientific Resources, Inc.
    Albuquerque, New Mexico 87114, United States
  • NYU Langone Ambulatory Care
    New York, New York 11201, United States
  • Medication Management, LLC
    Greensboro, North Carolina 27408, United States
  • Cape Fear Arthritis Care
    Leland, North Carolina 28451, United States
  • Carolina Arthritis Associates
    Wilmington, North Carolina 28401, United States
  • Trinity Medical Group
    Minot, North Dakota 58701, United States
  • Cincinnati Rheumatic Disease Study Group
    Cincinnati, Ohio 45242, United States
  • STAT Research, Inc.
    Dayton, Ohio 45417, United States
  • Clinical Research Source, Inc.
    Perrysburg, Ohio 43606, United States
  • Arthritis Group
    Philadelphia, Pennsylvania 19152, United States
  • Low Country Research Center
    Charleston, South Carolina 29486, United States
  • Amarillo Center for Clinical Research
    Amarillo, Texas 79124, United States
  • Austin Regional Clinic, P.A.
    Austin, Texas 78731, United States
  • Accurate Clinical Research, Inc.
    Baytown, Texas 77521, United States
  • Precision Comprehensive Clinical Research Solutions
    Grapevine, Texas 76034, United States
  • Therapeutic Concepts Rheumatology, LLC
    Houston, Texas 77004, United States
  • Rheumatology Clinic of Houston, P.A.
    Houston, Texas 77065, United States
  • Accurate Clinical Research, Inc.
    Houston, Texas 77089, United States
  • Pioneer Research Solutions, Inc.
    Houston, Texas 77429, United States
  • Accurate Clinical Research, Inc.
    League City, Texas 77573, United States
  • Endocrinology, Internal Medicine
    Lubbock, Texas 79410, United States
  • Dr. Alex De Jesus Rheumatology, P.A.
    San Antonio, Texas 78229, United States
  • Advanced Rheumatology of Houston
    Woodville, Texas 77382, United States
  • Centro de Investigaciones Medicas Mar del Plata
    Mar del Plata, Buenos Aires B7600FYK, Argentina
  • Instituto de Investigaciones Clinicas
    Mar del Plata, Buenos Aires B7600FZN, Argentina
  • Instituto de Investigaciones Clinicas Quilmes
    Quilmes, Buenos Aires B1878GEG, Argentina
  • Clinica de Higado y Aparato Digestivo
    Rosario, Santa Fe S2000CFJ, Argentina
  • Sanatorio San Martin
    Venado Tuerto, Santa Fe S2600KUE, Argentina
  • Centro Medico Privado de Reumatologia
    San Miguel de Tucuman, Tucuman T4000AXL, Argentina
  • Centro de Investigaciones Reumatológicas
    San Miguel de Tucuman, Tucuman T4000BRD, Argentina
  • Atencion Integral en Reumatologia (AIR)
    Ciudad Autonoma Buenos Aires, 1426, Argentina
  • Organizacion Medica de Investigacion (OMI)
    Ciudad Autonoma Buenos Aires, C1015ABO, Argentina
  • APRILLUS
    Ciudad Autonoma Buenos aires, C1046AAQ, Argentina
  • Instituto Centenario
    Ciudad Autonoma Buenos Aires, C1204AAD, Argentina
  • Hospital Privado Centro Medico de Cordoba S.A
    Cordoba, 5016, Argentina
  • Centro Polivalente de Asistencia e Inv. Clinica CER
    San Juan, 5400, Argentina
  • HUWC - UFC - Hospital Universitário Walter Cantídio - Universidade Federal do Ceará
    Fortaleza, Ceará 60430-370, Brazil
  • CEDOES - Diagnóstico e Pesquisa
    Vitória, Espírito Santo 29055450, Brazil
  • CIP - Centro Internacional de Pesquisa
    Goiânia, Goiás 74110-120, Brazil
  • CMiP - Centro Mineiro de Pesquisa
    Juiz de Fora, Minas Gerais 36010-570, Brazil
  • CETI - Centro de Estudos em Terapias Inovadoras Ltda.
    Curitiba, Paraná 80030-110, Brazil
  • Hospital Bruno Born
    Lajeado, Rio Grande Do Sul 95900-010, Brazil
  • LMK Serviços Médicos S/S Ltda
    Porto Alegre, Rio Grande Do Sul 90480-000, Brazil
  • Faculdade de Medicina do ABC
    Santo André, Sao Paulo 09060-650, Brazil
  • Centro Multidisciplinar de Estudos Clínicos - CEMEC
    Sao Bernardo Do Campo, Sao Paulo 09715-090, Brazil
  • Clínica de Neoplasias Litoral Ltda.
    Santa Catarina, 88301-215, Brazil
  • Associação de Assistência à Criança Deficiente - AACD
    Sao Paulo, 04032-060, Brazil
  • CPCLIN - Centro de Pesquisas Clínicas Ltda.
    São Paulo, 01228-200, Brazil
  • Centro de Reumatologia y Ortopedia SAS
    Barranquilla, 80020, Colombia
  • Centro de Investigacion en Reumatologia y Especialidades Medicas SAS. CIREEM
    Bogotá, 110221, Colombia
  • Medicity S.A.S.
    Bucaramanga, 680003, Colombia
  • Clinica de Artritis Temprana S.A.
    Cali, 76001, Colombia
  • Revmatologie MUDr. Klara Sirova s.r.o.
    Ostrava - Moravska Ostrava, 70200, Czechia
  • CCR Czech, a.s.
    Pardubice, 53002, Czechia
  • MEDICAL PLUS s.r.o.
    Uherske Hradiste, 68601, Czechia
  • PV - Medical, s.r.o.
    Zlin, 760 01, Czechia
  • Kerckhoff-Klinik gGmbH
    Bad Nauheim, Hessen 61231, Germany
  • SMO.MD GmbH
    Magdeburg, Sachsen Anhalt 39120, Germany
  • HRF Hamburger Rheuma Forschungszentrum
    Hamburg, 20095, Germany
  • Clinexpert Egeszsegugyi Szolg. es Ker. Kft.
    Budapest, 1033, Hungary
  • Obudai Egeszsegugyi Centrum
    Budapest, 1036, Hungary
  • MAV Korhaz és Rendelointezet
    Szolnok, 5000, Hungary
  • Vital Medical Center
    Veszprem, 8200, Hungary
  • Ajou University Hospital
    Suwon-si, Gyeonggi-do 443-380, Korea, Republic of
  • Chonnam National University Hospital
    Gwangju, 61469, Korea, Republic of
  • Hallym University Sacred Heart Hospital
    Gyeonggi-do, 431-796, Korea, Republic of
  • Severance Hospital, Yonsei University
    Seoul, 3722, Korea, Republic of
  • Centro de Investigacion Clínica GRAMEL S.C
    Mexico, Distrito Federal 03720, Mexico
  • Clinstile, S.A. de C.V.
    Mexico, Distrito Federal 06700, Mexico
  • Clinica de Investigacion en Reumatologia y Obesidad S.C.
    Guadalajara, Jalisco 44650, Mexico
  • Centro de Estudios de Investigacion Basica y Clinica SC
    Guadalajara, Jalisco 44690, Mexico
  • Accelerium S. de R.L. de C.V.
    Monterrey, Nuevo León 64000, Mexico
  • Universidad Autonoma de Nuevo Leon, Hospital Universitario Dr. Jose Eleuterio Gonzalez
    Monterrey, Nuevo León 64460, Mexico

Showing the first 100 of 116 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Feist E, Fatenejad S, Grishin S, Korneva E, Luggen ME, Nasonov E, Samsonov M, Smolen JS, Fleischmann RM. Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2022 Dec;81(12):1661-1668. doi: 10.1136/ard-2022-222630. Epub 2022 Sep 15. PubMed 36109142 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Sep 2019, 31 months.

Results were first posted in Jul 2021, 1 year 10 months after primary completion.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 31 months is above that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2016
First posted
May 3, 2016
StartActual
Jan 25, 2017
Primary completionActual
Sep 12, 2019
CompletionActual
Oct 1, 2019
Results first posted
Jul 21, 2021
Last update
Sep 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02760433
Collaborators
Quintiles, Inc., OCT Clinical Trials, Mene Research
Responsible party
Sponsor
First posted
May 3, 2016
Start date
Jan 25, 2017
Primary completion
Sep 12, 2019
Completion
Oct 1, 2019
Results posted
Jul 21, 2021
Last update
Sep 21, 2023

Study contacts

Mikhail Samsonov
study director · R-Pharm

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olokizumab

Start the discussion